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Primary biliary cirrhosis (PBC) is a chronic cholestatic liver
disease characterized by immunomediated destruction of the
small- and medium-sized intrahepatic bile ducts, mediated
by a selective loss of self-tolerance.1 Epidemiological and
genetic studies indicate that PBC is triggered in genetically
susceptible individuals following exposure to environmental
factors, including microbes and chemical compounds.2,3 Loss
of tolerance occurs either via molecular mimicry and/or the
formation of neoantigens and the development of cross
reactivity.4 This process results from dysfunction in both
innate and adaptive immunity, leading to the expansion of
autoreactive T- and B-lymphocyte populations.5 In PBC, the
multiorchestrated immune effector mechanisms lead to bile
duct injury.
Immune Tolerance and the “Liver Tolerance
Effect”
In the 1890s, Paul Ehrlich described a phenomenon inwhich a
host immune system turns on itself, attacking and damaging
its own organs and tissues. He coined the term “horror
autotoxicus” to describe how the phenomenon is teleologi-
cally impossible and that nature would or should not allow
this to happen. As a result, despite research supporting the
existence of autoimmunity early in the 20th century, little
attention was paid to the concept of immune tolerance. The
discipline of autoimmunity was eventually recognized by the
1940s, and in the ensuing 20 years, an appreciation of the
pathogenesis of rheumatoid arthritis and systemic lupus
erythematosus was increasingly attributed to an autoim-
mune phenomenon. In 1948, Frank Macfarlane Burnet de-
duced the nature of immunological inertness to self, ﬁrst
naming this as “tolerance” and then proposing it to be a
characteristic acquired in developmental life rather than
innately as earlier believed.6,7 In 1953, Medawar and his
colleagues experimentally demonstrated the induction of
immune tolerance in inbredmice.8Ultimately, the conception
of immune tolerance was deﬁned as an ability of the immune
system to prevent itself from targeting self-molecules, cells,
or tissues; this has led to seminal research in our understand-
ing of autoimmunity.9
The hallmark of the immune system is its ability to
maintain this tolerance to self-antigens, and yet still be able
to mount effective immune responses against pathogens and
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Abstract In primary biliary cirrhosis (PBC), the breach of tolerance that leads to active disease
involves a disruption in several layers of control, including central tolerance, peripheral
anergy, a “liver tolerance effect,” and the action of T regulatory cells and their related
cytokines. Each of these control mechanisms plays a role in preventing an immune
response against self, but all of them act in concert to generate effective protection
against autoimmunity without compromising the ability of the host immune system to
mount an effective response to pathogens. At the same time, genetic susceptibility,
environmental factors, including infection agents and xenobiotics, play important roles
in breach of tolerance in the development of PBC.
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malignant cells (danger signals). Breaking the balance be-
tween tolerance and immunity can lead to disease manifes-
tations, resulting in infections, neoplasia, or autoimmunity.
To avoid harmful self-reactivity, self-tolerance within the T-
and B-cell repertoire are achieved through central and pe-
ripheral tolerance mechanisms.
Central tolerance in the thymus and bonemarrow play key
roles in shaping immune system homeostasis, especially in
early life. In the thymus, with no marked reactivity against
self-peptides, developing lymphocytes undergo positive se-
lection in the thymic cortex, then become mature lympho-
cytes and enter the circulation. Conversely, developing
lymphocytes with marked reactivity against self-peptides
are negatively selected and deleted in the thymic medul-
la.10–14 After exiting the thymus, mature T cells are subjected
to secondary selection (peripheral tolerance) by which the
majority of self-reactive T cells are deleted or rendered
anergic.15,16 Meanwhile, when immature B cells express
surface IgM that recognize ubiquitous self-cell-surface anti-
gens, they are eliminated by a process known as clonal
deletion or anergy.17 Autoreactive B cells can escape deletion
by a process known as receptor editing.18,19Mature B cells are
also under the control of peripheral tolerance.20
Abundant evidence suggests that even under the regula-
tion of central and peripheral tolerance, small numbers of
potentially hazardous self-reactive lymphocytes still can
“leak out” into the periphery in normal individuals.21,22 But
these residual self-reactive T cells normally remain in an
inactive state due to several factors, including lack of costi-
mulation from antigen-presenting cells, low avidities of their
T-cell receptors (TCRs) for self-antigens, or seclusion of self-
antigens.23 At the same time, mature self-reacting B cells may
survive intact and rarely be activated because they need
costimulatory signals from T cells, as well as the presence
of its recognized antigen to proliferate and produce
antibodies.
In addition to these passive mechanisms, evidence indi-
cates that suppressive regulatory mechanisms also exist.
CD4 þ CD25þ T regulatory cells (Tregs) are immune regula-
tory cells that play an important role in immune homeostasis.
These cells are involved in themaintenance of peripheral self-
tolerance and downregulation of immune responses.24–26
PDCD5 acetylates FOXP3 and affects Treg cell modulation of
immune function, thereby playing a role in the development
of autoimmune disease.27
Liver tissue itself also possesses the ability tomediate local
and systemic tolerance to self and foreign antigens.28 This is
known as the “liver tolerance effect.” The liver is a depot for
clearance of toxins and metabolic products that result from
physiologic and pathogenic processes. Thus, there is a need to
prevent activation of the immune system by exposure to
“nonpathogenic”molecules (including food components) and
microorganisms (gut microﬂora), while continuing to mount
an effective immune response against pathogens.29,30 Non-
parenchymal liver cells including the liver sinusoidal endo-
thelial cells, resident DCs, Kupffer cells, and hepatic stellate
cells are likely responsible for hepatic tolerance. These cells
can generate anti-inﬂammatory cytokines including IL-10
and TGFβ or express the negative costimulators of T-cell
activation that mediate immune suppression, such as pro-
grammed cell death ligand-1 (PD-L1).31,32 In addition, hep-
atocytes and Treg cells are also involved in mediating T-cell
tolerance in the liver.
The normal physiologic mechanisms of immune tolerance
should prevent autoimmune diseases. The concept of auto-
immunity is often thought to require the presence of auto-
antibodies (antibodies directed against normal self-tissues or
substances).33,34 However, autoimmunity may exist in the
absence of a known autoantigen. Autoimmunity generally
results from a defect in central tolerance mechanisms that
allows the generation and proliferation of a limited number of
autoreactive cells, which canmature and enter the periphery.
However, it has been repeatedly demonstrated in animal and
human studies that the presence of autoreactive cells does
not universally lead to autoimmune disease. A breach of
tolerance that occasionally occurs during the process of
mounting an immune response to a pathogen is often, but
not always the trigger for the development of autoimmune
diseases. Autoimmune diseases are generally classiﬁed on the
basis of the organ or tissue involved. Autoimmune diseases
that are restricted to speciﬁc organs of the body are known as
organ-speciﬁc autoimmune diseases, including type 1 diabe-
tesmellitus,multiple sclerosis, PBC, and psoriasis. Conversely,
if many tissues of the body are affected, the disease is
regarded as a systemic autoimmune disease, such as systemic
lupus erythematosus and rheumatoid arthritis.
Primary Biliary Cirrhosis and a Breach of
Tolerance
In 1851, Addison and Gull ﬁrst described nonobstructive
biliary cirrhosis. The disease was further characterized clini-
cally by Ahrens et al in 1950. After a considerable period of
research inactivity, a cDNAencoding the autoantigen targeted
by these antimitochondrial antibodies (AMAs) was cloned in
1987 by Gershwin and colleagues.35 Subsequently, the anti-
gen was identiﬁed as the E2 subunit (E2) of the pyruvate
dehydrogenase complex (PDC).36 More recently, other auto-
antibodies have been detected in PBC patients, including
those directed against the nuclear pore complex (NPC).37 A
series of interrelated immunoreactive events have been
discovered to occur in primary biliary cirrhosis, which
upon characterization will contribute to our understanding
of the mechanisms of breach of tolerance (►Fig. 1).
Primary biliary cirrhosis, with the presence of autoanti-
bodies (AMAs), PDC-E2-speciﬁc autoreactive CD4, CD8 T cells,
autoreactive B lymphocytes in liver tissue, and three separate
genetically based mouse models,38–40 fulﬁlls the criteria for
an autoimmune disease.41 Autoimmune mechanisms of PBC
are multifactorial,42 consisting of a breakdown in central or
peripheral tolerance, as well as the aforementioned liver
tolerance effect.
Speciﬁcally, the loss of tolerance in PBC patients may occur
as a result of three main conceptual mechanisms: (1) molec-
ular mimicry and the presence of neoantigens, developed
through cross reactivity to PDC-E2; (2) a genetic
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susceptibility, responsible for inheritable abnormalities in the
regulation of immune responses; and (3) an imbalance in the
immune system, leading to an overactive innate immune
system, which inappropriately activates nonspeciﬁc immune
responses that lead to the expansion of autoreactive popula-
tions of T and B lymphocytes (►Fig. 2).
Mitochondrial Autoantigens in Primary
Biliary Cirrhosis
The 2-oxoacid dehydrogenase complex (2-OADC) autoanti-
gens are multienzyme complexes essential in the mitochon-
drial respiratory chain.43 This enzyme family includes three
Fig. 2 Mechanisms that are involved in breaching immune tolerance in primary biliary cirrhosis. The breach of tolerance that leads to active
disease involves a disruption in several layers of control, including central tolerance, peripheral anergy, a “liver tolerance effect,” and the action of
T regulatory cells and their related cytokines. At the same time, genetic susceptibility, environmental factors, including infection agents and
xenobiotics, also play important roles in breach tolerance.
Fig. 1 Timeline of identifying immune parameters in primary biliary cirrhosis (PBC). Black, clinical immunology-related events and conception;
blue, innate immunity; red, adaptive immunity; green, PBC mouse models. AMA, antimitochondrial antibody; BD, biliary ducts; DC, dendritic cell;
NK, natural killer; NKT, Natural killer T; TLR, Toll-like receptor.
Seminars in Liver Disease Vol. 34 No. 3/2014
Breach of Tolerance: Primary Biliary Cirrhosis L. Wang et al. 299
D
ow
nl
oa
de
d 
by
: I
P-
Pr
ox
y 
Th
om
as
 J
ef
fe
rs
on
 U
ni
ve
rs
ity
, S
co
tt 
M
em
or
ia
l L
ib
ra
ry
, A
IS
R.
 C
op
yr
ig
ht
ed
 m
at
er
ia
l.
complexes: PDC, the 2-oxo glutarate dehydrogenase complex
(OGDC), and the branched chain 2-oxoacid dehydrogenase
complex (BCOADC). Each of the three complexes consists of
three subunits: E1, E2, and E3. Antimitochondrial antibodies
speciﬁcally recognize the lipoylated domains of the 2-OADC
family of enzymes, and all immunodominant epitopes con-
tain an ExDKA (glutamic acid -E-, x, aspartic acid, -D-, lysine –
k-, and alanine –A-) motif, with lipoic acid attached to K at
position 173. This conﬁguration is necessary and/or sufﬁcient
for antigen recognition. Interestingly, there are only ﬁve
proteins in mammals that contain lipoic acid, and four of
the ﬁve are autoantigens in PBC. Among the 2-OADC con-
stituents, themajor autoantigen is the PDC-E2, which was the
antigen ﬁrst cloned in 198735; less frequent autoantigens
include OADC-E2, BCOADC-E2, and E3BP.44
In autoimmunity, the paradox is that autoantigens are
unable to elicit a primary immune response themselves, but
can be recognized as targets for effector T cells stimulated by a
pathogenic cross-reactive epitope. To break self-tolerance to
the autoantigen, the epitope mimic or mimotope needs to
induce activation and proliferation rather than anergy of
autoreactive T cells. Subsequently, the autoantigen presented
by the host cells of a certain tissue must be recognized by
reactive epitope-speciﬁc T cells. In the case of PBC, either a
mimotope carried by a microbe or a neoantigen generated by
xenobiotic-modiﬁed self-antigen can mimic mitochondrial
proteins, and subsequently may activate autoreactive lym-
phocytes that have leaked out into the peripheral repertoire.
The process may become self-perpetuating because of the
cross-reactive unmodiﬁed self-antigens (►Fig. 3).45
Molecular Mimicry of PDC-E2 and Cross Reactivity
Two triggers, infections and xenobiotics, have been exten-
sively investigated with regard to their role in molecular
mimicry. Central to molecular mimicry is the ability of
microorganisms that contain immunogenic epitopes (similar
to self-antigens) to trigger a cross-species immune re-
sponse.46 Xenobiotics are chemicals that can generate a loss
of tolerance to self-proteins, usually as a result of changed
immunogenicity through alteration of or complexing to
either self-proteins or nonself-proteins.47,48
Molecular Mimicry
In 1964, the term “molecular mimicry” was coined by Dam-
ian, who suggested that select antigenic determinants of
microorganisms may resemble host epitopes.49 Numerous
speciﬁc infectious agents, mainly bacteria (both gram nega-
tive and positive), and viruses (herpes simplex viral,50mouse
mammary tumor virus,51,52 and Epstein-Barr virus53), para-
sites (trypanosomes and Ascaridiagalli54), and fungi (Saccha-
romyces cerevisiae55), have been implicated in PBC.56 The
classic example is Escherichia coli and it has been reported
that urinary tract infections (UTIs) are frequently observed in
PBC.57 Sera from PBC patients react with both E. coli and
human PDC-E2. We also note that Novosphingobium aroma-
ticivorans, a gram-negative bacterium, contains two proteins
that share highly homologous amino-acid sequenceswith the
immunodominant epitope of PDC-E2. Speciﬁc antibody re-
actions to this organism have also been detected in PBC
patients, and in fact exhibit up to a 1000-fold stronger
response than those against E. coli.58 In addition, a peptide
derived from Pseudomonas aeruginosa has been found to be
partially homologous to PDC-E2159–167, which is the HLA-
A0201-restricted epitope of PDC-E2 recognized by autoreac-
tive cytotoxic T lymphocytes in PBC (►Table 1).59
Autoimmune cholangiopathy, which possesses some sim-
ilarity to human PBC, has occurred after exposure to bacterial
components. Lipopolysaccharide (LPS), a speciﬁc component
of gram-negative bacterial cell walls, injected intomice either
alone or in combinationwith PDC-E2, induces the appearance
of portal lymphocytic inﬁltration and cholangiocyte degen-
eration such as that seen in human PBC liver.60 Furthermore,
lipoteichoic acid (LTA), a gram-positive cell wall component,
is also involved in systemic multifocal epithelial inﬂamma-
tion in chronic colitis-harboring TCRα(/  )xAIM(/  )
mice.61 Serum levels of LTA-speciﬁc IgA are also signiﬁcantly
higher in PBC than in normal controls.62 Unmethylated CpG
motifs from bacterial DNA triggers a PDC-speciﬁc Th1 re-
sponse in peripheral blood mononuclear cells (PBMCs) from
mice immunized with PDC.63
Most studies supporting the role of infectious agents in the
pathogenesis of PBC are based on linear or conformational
mimicry between microbial proteins and human mitochon-
drial antigens. Shared sequences between human and micro-
bial proteins can disrupt immune toleranceby inducing cross-
reactive antibodies or effector T cells and/or by promoting
epitope spreading.64 However, controversy surrounding the
concept of infectious agents and their components in the
etiology of PBC still exists.65,66
Fig. 3 Molecular mimicry of PDC-E2 helps breach tolerance in primary
biliary cirrhosis (PBC) patients. (1) Infectious agents (E. coli, viral
pathogens) and xenobiotics can be recognized and phagocytosed by
antigen-presenting cells (APCs); (2) APCs process and present molec-
ular mimicry of PDC-E2 to CD4 or CD8 T cells by MHC-II or MHC-I; (3)
autoreactive CD4 T, CD8 T cells are activated, and CD4 T cells provide
help to autoreactive B cells to produce antimitochondrial antibodies
(AMA), which lead to the breach of tolerance; (4) intact PDC-E2
released from biliary epithelial cells recognized by reactive epitope-
speciﬁc T cells lead to PBC.
Seminars in Liver Disease Vol. 34 No. 3/2014
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Xenobiotics
Self- or nonself-proteins can be modiﬁed by chemical com-
pounds (i.e., xenobiotics) causing a change in molecular
structure that enhances immunogenicity. Xenobiotics are
important in PBC because many environmental chemicals
aremetabolized primarily in the liver and duringmetabolism,
may form reactive metabolites that can modify cellular
proteins to form neoantigens. Sufﬁcient data exist supporting
the hypothesis that xenobiotic-induced and/or oxidative
modiﬁcation of mitochondrial autoantigens is a critical step
leading to loss of tolerance for PBC patients.67 As previously
noted, lipoic acid is a critical component of the PDC-E2
epitope. Moreover, lipoic acid, at the exterior of the PDC-E2
protein complex, is accessible to chemical modiﬁcation.
In 2001, Gershwin and his colleagues replaced the lipoic
acid moiety with synthetic structures designed to mimic a
xenobiotically modiﬁed lipoyl hapten and subsequently
quantiﬁed the reactivity of these structures with sera from
PBC patients. The data demonstrate that AMAs from seropos-
itive patientswith PBC, but not controls, reacted against three
of 18 organically modiﬁed autoepitopes signiﬁcantly better
than to the native domain,47 suggesting an organic compound
may modify a self-protein and serve as a mimotope.
In 2003, the Gershwin laboratory replaced the lipoic acid
moiety of PDC-E2 with a collection of synthetic structures
designed to mimic a xenobiotically modiﬁed lipoyl hapten on
a 12-aa peptide, leading to signiﬁcantly higher reactivitywith
AMA. Based on these data, they immunized rabbits with the
xenobiotic, 6-bromohexanoate, bovine serum albumin con-
jugate, and induced AMAproductionwithout requirement for
the peptide backbone of PDC-E2.68 These autoantibodies
disappeared when the stimulus was discontinued. In 2007,
the same group reported that oxidative stress-induced liver
damage leads to a transiently higher frequency of AMA
induction, especially in subjects with acetaminophen
(APAP) poisoning.69
In 2011,quantitative structure-activity relationship
(QSAR) analysis was performed on a focused panel of lipoic
acid mimics in which the lipoyl disulﬁde bond was modi-
ﬁed.706,8-bis(acetylthio)octanoic acid (SAc), 8-(acetylthio)
octanoic acid (OASAc), and 6,8- bis(propionylthio)octanoic
acid (SCOEt) were highly reactive to sera from AMA-positive
PBC patients, at levels even higher than the reactivity against
lipoic-acid-conjugated PDC-E2 peptide. Furthermore, two of
these compounds (6-bromohexanoate and 2-octynoic acid71)
were capable of inducing AMA and PBC-like liver lesions in
guinea pigs72 and NOD.110173 or C57BL/674mice, respective-
ly. These models illustrate breakdown of tolerance in the
absence of exposure to PDC-E2.
Interestingly, 2-octynoic acid is found in several cosmetic
products including nail polish; their frequent use among
women may contribute to the female predominance of
PBC.75,76
Apoptosis
The clearance of apoptotic cells is normally associatedwith an
anti-inﬂammatory response; this process plays an important
role in tissue homeostasis and immune tolerance.77,78 More-
over, increasing evidence suggests that failure in clearance of
apoptotic cell debris is linked to the breakdown of tolerance
and the development of autoimmunity.79–81 Apoptosis of
biliary epithelial cells (BECs) has been proposed as a potential
source of neoantigens that are responsible for activating
autoreactive lymphocytes.82Autophagy, the catabolic process
Table 1 Molecular mimicry and neoantigens to PDC-E2
Epitope mimic or mimotope Cross reactivity References
Molecular mimicry
Escherichia coli PDC-E2212–226, PDC-E2 163–176 Ab and CD4
207,245
Novosphingobium aromaticivorans PDC-E2 208–237 Ab
84,246
Helicobacter pylori PDC-E2 212–226 Only in mouse models
247,248
Pseudomonas aeruginosa PDC-E2 159–167 CD8 TCR
59
Haemophilus inﬂuenzae PDC-E2 212–226 Ab
245
Lactobacillus delbrueckii PDC-E2 212–226 Ab
249
Mycoplasma pneumoniae PDC Ab 250
Mycobacterium gordonae PDC-E2 212–226 Ab
251
Borrelia burgdorferi PDC-E2 208–235 Ab
252
Xenobiotics
Lipoic acid moiety replacement Lipoic acid mimics AMA 47
6-bromohexanoate 12-aa replacement within
lipoic acid moiety
AMA 68
2-octynoic acid PDC-E2 AMA 71
Structure-activity
relationship (QSAR) analysis
Lipoic acid mimics AMA 70
Seminars in Liver Disease Vol. 34 No. 3/2014
Breach of Tolerance: Primary Biliary Cirrhosis L. Wang et al. 301
D
ow
nl
oa
de
d 
by
: I
P-
Pr
ox
y 
Th
om
as
 J
ef
fe
rs
on
 U
ni
ve
rs
ity
, S
co
tt 
M
em
or
ia
l L
ib
ra
ry
, A
IS
R.
 C
op
yr
ig
ht
ed
 m
at
er
ia
l.
that leads to cell destruction and the clearance of the resul-
tant cellular debris may also play a signiﬁcant role in autoim-
mune diseases.83
Mitochondrial antigens are ubiquitously expressed in all
nucleated cells, and are phylogenetically highly conserved.84
During spontaneous or induced apoptosis, almost all cell
types express mitochondrial antigens on the intact plasma
membrane and within apoptotic blebs. The apoptotic cells
acquire the ability to initiate an autoimmune response by
presentation of 2-OADC-derived autoantigens.85 In most cell
types, the release of lysine-lipoylated sequences from mito-
chondria during apoptosis leads to oxidation by gluta-
thiones.86 The oxidated forms are not immunogenic and
are not recognized by serum AMA because glutathionylation
masks autoantibody recognition.87 Cholangiocytes fail to
covalently link glutathione to lysine-lipoyl groups during
apoptosis and immunogenicity is retained. The intact PDC-
E2 in apoptotic fragments can then be taken up by local
antigen-presenting cells and transferred to regional lymph
nodes for priming of cognate T cells. Lleo and colleagues ﬁrst
reported the presence of PDC-E2 in the blebs of human
intrahepatic bile duct cells that were undergoing apoptosis.77
Autoantigens found in apoptotic blebs (apotopes) were sub-
sequently taken up by macrophages.88 Further study showed
that addition of serum AMA to a coculture of macrophages
and apotopes led to a signiﬁcant increase in proinﬂammatory
cytokine secretion. However, the blocking of CD16 mediated
complement receptor 3 (CR3) signaling, possibly resulting
from the serum anti-CD16 IgM autoantibodies found in PBC,
may be related to the delayed clearance of apoptotic BECs by
macrophages.89
The unique characteristics of BECs during apoptosis might
constitute the pathogenic link between the ubiquitous distri-
bution and high degree of conservation across species of the
AMA autoantigen and the organ speciﬁcity of PBC
pathology.85
Genetics and Autoimmunity in PBC
There is a broadly accepted paradigm that genetic suscepti-
bility results in a breakdown in immunological tolerance that
may enhance the effect of autoantigens and the degree of an
abnormal immune response. Speciﬁcally, the role of genetic
factors in conferring PBC susceptibility has been widely
demonstrated (►Fig. 4). The relative risk of a family member
of a ﬁrst-degree relative of PBC patients is 50- to 100-fold
higher than the general population.90 By evaluating the
concordance of PBC in a genetically deﬁned population of
twin sets (including monozygotic and dizygotic twins), ge-
netic susceptibility was further conﬁrmed.91,92 In addition,
the signiﬁcant female preponderance is well known and the
median odds ratio in case studies corresponds to a female
predominance of up to 9:1 to 10:1, among the highest
described in autoimmune diseases.
Human Leukocyte Antigen
The major histocompatibility complex (MHC) is located on
the short arm of chromosome 6 and harbors genes encoding
molecules involved in antigen presentation, and is therefore
involved in distinguishing self from non-self. The MHC com-
plex is characterized by a cluster of genes related by sequence
homology and/or function: the human leukocyte antigen
Fig. 4 Genetic factors that confer primary biliary cirrhosis (PBC) susceptibility. The relationship between genetic susceptibility and the breach of
tolerance in PBC is complex, involving human leukocyte antigens (HLA), nonhuman leukocyte antigens, antigen risk loci, epigenetics, and sex-
associated factors.
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(HLA) class I andHLA class II genes encoding proteins involved
in antigen presentation. HLA class III genes encode several
other immune proteins, such as tumor necrosis factor-α (TNF-
α).93 Unlike other autoimmune diseases, there are only weak
and regional associations between PBC and HLA mole-
cules.90,94–96 In HLA candidate gene studies based on pop-
ulations of European origin, PBC is associated with the risk
haplotypes, DRB108:01-DQA104:01-DQB104:02 and
DRB104:04-DQB103:02.97,98 Primary biliary cirrhosis is
also associated with the protective haplotypes DRB111:01-
DQA05:01-DQB103:01 and DRB115:01-DRA101:02-
DQB106: 02. In Japan, DRB108:03-DQB106:01 and
DRB104:05-DQB104:01 have been identiﬁed as risk hap-
lotypes, whereas DRB113:02-DQB106:04, DRB111:01-
DQB103:01, and DRB115:01 act as protective haplotypes.99
In a study by Invernizzi et al, conditional analysis showed that
these haplotype associations in Italians are most likely driven
by the respective DRB1 alleles, the risk alleles DRB108 and
DRB114, and the protective allele DRB111.100
No consistent and reproducible associations have been
detected between speciﬁc DRB1 alleles and clinical features of
the disease. In Chinese PBC patients, signiﬁcant association
exists between HLA-DRB108:03, DQ2, and DQB106:01 al-
leles and PBC. DRB108:03-DQB106:01 and DRB107:01-
DQB102:02 haplotypes were also associated with PBC sus-
ceptibility. On the other hand, DRB103:01 alleles and the
DRB112:02-DQB103:01 haplotype were signiﬁcantly de-
creased in Chinese PBC patients compared with controls.101
Genome-Wide Association Studies
Genome-wide association study (GWAS) analysis demon-
strates that there is less of a difference in the intensity of
risk association with PBC between HLA and non-HLA loci.
This ﬁnding suggests that although HLA is a very important
contributor of risk, the non-HLA loci, as a group, are at least
equally important. So far, 27 genome-wide signiﬁcant non-
HLA risk loci for PBC have been identiﬁed,102 including
2q32 (STAT1, STAT4), 3q25 (IL12A, SCHIP1), 7q32 (IRF5,
TNPO3), 11q23(CXCR5),12p13 (TNFRSF1A, LTBR), 16p13.13
(SOCS1, CLEC16A), 17q12 (IKZF3) and 19q13.3 (SPIB).98,103
Risk loci for PBC appear to be enriched for gene products
involved in innate or adaptive immune responses, consis-
tent with an autoimmune component to pathogenesis.
Genome-wide association studies now play a signiﬁcant
role in evaluating a genetic role in many autoimmune
hepatic diseases.102
In 2009, Hirschﬁeld et al identiﬁed three susceptibility
loci, HLA, IL12A, and IL12RB2, and their observations were
conﬁrmed by other GWAS studies.104 IL-12,acting as a T-cell
stimulating factor that is involved in the differentiation of
naive T cells into Th1 cells, has been previously implicated in
autoimmunity and is important for the development of
antigen-speciﬁc (PDC-E2) autoreactive T cells in PBC.105 IL-
12 is also involved in the activity of natural killer (NK) cells
and its cytotoxic activity. In addition, the binding of IL-12 to
its receptor is thought tomodulate autoimmune responses by
evoking IFN-γ production, which may in turn alter IL-23-
driven induction of IL-17-producing Th17 lymphocytes.
Moreover, signals from IL-12R are mediated by TYK2 and
STAT4, and negatively regulated by SOCS1.106,107
IRF5-TNPO3 (encoding interferon regulatory factor 5 and
transportin 3) plays a key role in the innate immune response
as part of the Toll-like receptor (TLR) signaling pathway and
mediates apoptosis induced by TNF related apoptosis-in-
duced ligand.108 IRF5 also contributes to the development
of dendritic cells, and promotes inﬂammatory macrophage
polarization and Th1-Th17 responses109
CXCR5 (Chemokine (C-X-C Motif) Receptor 5), acting as a
multipass membrane protein, is mainly expressed in mature
B cells and follicular helper-T cells (Tfh). Expression of CXCR5
affects the migration of B cells into splenic follicles, and may
have a regulatory role in B-cell differentiation. Moreover,
CXCR5 also affects the function of Tfh cells, which have been
reported to play an important role in multiple autoimmune
diseases.110
The transcription factor IKZF3 gene encodes IKAROS fami-
ly zinc ﬁnger 3 (also known as Aiolos) and plays a critical
regulation role in B-cell differentiation, proliferation, and
maturation. It also controls apoptosis of T and B cells in an
IL-2-dependent way, and has been implicated in the patho-
genesis of autoimmunity.111 Spi-B (Spi-B transcription factor
[Spi-1/PU.1 related]), a member of the ETS transcription
factor family, is an important mediator of both early T-cell
lineage differentiation and B-cell receptor signaling. Spi-B
also induces the development of plasmacytoid dendritic cells
and NK cells.
Other new candidate genes associated with disease at
GWAS thresholds include SIAE, TNFSF15, POU2AF1, CTLA-4,
IL-1, IL-10, vitamin D receptor (VDR), DENND1B, CD80, IL7R,
CLEC16A, PTPN22, and NFKB1,112–118 all of which play com-
pelling roles in the development of autoimmunity that re-
quire further conﬁrmation or investigation.
Epigenetics
Epigenetics is deﬁned as stable and heritable patterns of gene
expression that do not involve any alterations to the original
DNA sequence. There are four known types of epigenetic
mechanisms: (1) methylation of DNA on certain cytosine
residues that generally silences genes, (2) posttranslational
modiﬁcations of histone tails of nucleosomes (acetylation,
methylation, ubiquitination, etc.) that may either render
genes active or inactive depending on the histone modiﬁed
and the nature of the modiﬁcation, (3) active remodeling of
chromatin by protein machines called remodeling complexes
that can also either enhance or suppress, and (4) the silencing
of gene expression by small noncoding RNA transcripts.119
The lackof concordance inmonozygotic twins in autoimmune
diseases strongly suggests that besides environmental fac-
tors, epigenetic factors may also be important in determining
the susceptibility to autoimmunity.9,120,121 The relationship
between epigenetics and the pathogenesis of autoimmune
diseases, including PBC, has been described
extensively.91,122–125
The interaction of CD40 and CD40L plays a key role in
CD4þ T cell priming, B-cell terminal maturation, and immu-
noglobulin class-switch recombination. No gene mutations
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were detected in cDNA of CD40L from PBC patients by RT-
PCR-SSCP technique.126 Lleo et al has demonstrated signiﬁ-
cantly lower levels of DNAmethylation of the CD40L promot-
er in CD4 þ T cells from PBC patients, as compared with
controls, and this decreased methylation inversely correlated
with levels of serum IgM in PBC patients.127
The reason for female predominance is unclear, although
multiple theories have been proposed.128–138 Because the
female has two X chromosomes, one is silenced to varying
degrees in a processknownasX-chromosome inactivation (XCI)
or lyonization. Most genes on the inactive X chromosome are
silenced by promoter methylation during X-chromosome in-
activation (XCI).139Twogenes (CLIC2 and PIN4)were identiﬁed
as consistently downregulated in an effected cohort of mono-
zygotic twin sets discordant and concordant for PBC. Both
CLIC2 and PIN4 demonstrated partial and variablemethylation
of CpG, but the possible mechanisms by which epigenetic
factors inﬂuence PBC onset are likelymuchmore complex than
a simple X-linking of candidate genes.120,140–142
MicroRNAs play a vital role in the regulation of various
aspects of immune function and in the development of auto-
immune disease. In 2009, it was shown that PBC is associated
with altered expression of 35 hepatic microRNAs.143 Subse-
quently, 17microRNAs differentially expressed in PBMCs from
PBC patientswere also identiﬁed.144OthermicroRNAs, such as
miR-506,145 miR-let-7b, miR-505–3p, and miR-197–3p have
also been reported to be associated with PBC.146,147 However,
the precise mechanisms related to the role of microRNA in the
maintenance of the breach of immune tolerance in PBC have
yet to be elucidated.
Finally, a considerable number of sex-related genes appear
crucial in the maintenance of physiological sex hormone
Fig. 5 Innate and adaptive immunity in primary biliary cirrhosis (PBC) patients. (1) Microorganism proteins, xenobiotics, and apoptosis of biliary
epithelial cells (BEC) can be recognized and endocytosed by antigen-presenting cells (APCs), which subsequently activate innate immune cells
such as Toll-like receptors (TLRs), DCs, macrophages, natural killer (NK) and natural killer T (NKT) cells, and others. (2) After being processed by
APCs, some T-cell immunogenic peptides were generated and presented to uncommitted T helper (Th0) lymphocytes and CD8 T cells. (3)
Activated Th0 cells then differentiate into Th1, Th2, Tfh, and Th17 cells. Furthermore, Th1 cells secrete cytokines such as interleukin-2 (IL-2) and
interferon-γ, which stimulate development of cytotoxic T lymphocytes (CTL).Th2 cells or Tfh cells secrete IL-4, IL-10, IL-13, or IL-21, and may
stimulate autoantibody (e.g., AMA) production by B lymphocytes. Finally, CTL (autoreactive CD8þ T), B lymphocytes, Th17, autoreactive
CD4 þ T, NK, and NKT inﬁltrate and gather around the small bile duct, and participate in the development of autoimmunity. (4) Simultaneously,
the number and function of immunosuppressive cells (Treg, Breg, Tr1, and CD8 Treg) decrease signiﬁcantly, which indirectly promotes
overactivation of immune responsiveness. Throughout the process, the balance between immune tolerance and break tolerance is a constantly
changing process, which ﬁnally leads to the breach of tolerance in PBC.
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levels. Often, these genes have a pleotropic function in
immune system balance.148 Sex-associated hormones, such
as estrogens, androgens and prolactin, which not only differ
betweenmales and females but also canvary according to age,
can be central to the T helper 1/T helper 2 balance. They may
therefore play a signiﬁcant role in determining an appropriate
or inappropriate inﬂammatory response and thus play a role
in the balance between immune tolerance and autoimmuni-
ty.149 Invernizzi et al150ﬁrst determined a signiﬁcantly higher
frequency of monosomy of the X chromosome in peripheral
leukocytes (particularly T and B cells) in female PBC subjects
as compared with age-matched female controls. Moreover,
several sex-related factors (pregnancies,151 contraceptives,
estrogen-replacement treatments,75 and recurrent vagini-
tis152) appear to increase the risk of developing PBC. The
availability of high-throughput efforts to sequence exomes
and genomes and the advent of deep-sequencing should
advance these data.
Innate and Adaptive Immunity
Defects in immune regulation that govern components of
both innate andadaptive immunity contribute to the abnormal
perpetuation of the immune response (►Fig. 5; ►Table 2).
Innate immune cells physiologically resident in the liver
constantly provide a defense against pathogens while main-
taining tolerance to food antigens and commensal bacteria.
The evidence for a role of innate immunity in PBC includes the
following immunological features: presence of granulomatous
inﬂammation, elevated levels of polyclonal IgM, hyperrespon-
siveness to CpG, increased levels of NK cells, and aberrant
cytokine responses.153,154
Toll-Like Receptors
Thirteen Toll-like receptors (TLRs) have been described in
mammals of which 10 are found in humans.155 Toll-like
receptors are part of a system of pattern-recognition
Table 2 Innate and adaptive immune in patients with primary biliary cirrhosis
Immune type Function Reference
Innate immunity
TLR TLR signaling; contributes to the breach of tolerance 154,157
DC " Number (peripheral and intrahepatic) " Function
(presenting and cross presenting)
163,164,166
Macrophage " Hypersecretion of proinﬂammatory cytokines 168,253
BEC Act as antigen presenting cells; defense against
pathogenesis; induces IgA-related damage
173,175,180
NK " Number (peripheral and intrahepatic) " Function
(cytotoxic activity)
184,185
NKT " Number (peripheral and intrahepatic)
"Function(cytotoxic activity, perforin expression)
" Lymphoid cell inﬁltration
187,188
Adaptive immunity-Cellular immunity
CD4 ""Autoreactive CD4 T cells (100- to150-fold)
"Ratio of Th1/Th2
190,191,203
Th17 "Number (intrahepatic) "IL-17 secretion 192–194
Treg ↓ Number (peripheral and intrahepatic)
↓ Function (maintenance self-tolerance)
195,196
Tfh " Number (peripheral and intrahepatic)
" Function (provides help to B cells)
CD8 " Autoreactive CD8 T cells (10-fold)
" Function (cytotoxic activity)
59,208
- Humoral immunity
Antibodies Indicates a breach of immune tolerance
(AMA, AMA-IgA, ANA, anti-Gp120 and anti-Sp100)
211,212
B cells " Number (peripheral and intrahepatic)
" Intrahepatic CD38þ plasmablast
"Function (promote antibody production)
Suppressive B cells exist (Breg)
38,214,215,254
Abbreviations: AMA, antimitochondrial antibody; ANA, antinuclear antibody; BEC, biliary epithelial cell; DC, dendritic cell; IgA, immunoglobulin A; NK,
natural killer; NKT, natural killer T; TLR, Toll-like receptor.
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receptors (PRRs) that act by recognizing unique, highly
conserved structural components of bacteria, fungi, viruses
called pathogen-associated molecular patterns (PAMPS), as
well as damage-associated molecular patterns (DAMPs). The
binding of PAMPs or DAMPS to TLRs leads to signaling path-
ways that activate and propagate innate and adaptive inﬂam-
matory responses.156
The expression of TLRs is normally regulated by a negative
signaling pathway in the liver, which prevents inappropriate
activation of inﬂammation. Peripheral blood mononuclear
cells in PBC patients produce higher amounts of inﬂammato-
ry cytokines in response to the ligands of TLR2, TLR3, TLR4,
TLR5, and TLR9 than PBMCs in healthy subjects.157 In PBC
patients, peripheral B cells exposed to CpG motifs express
increased amounts of TRL9 and CD86, which enhance their
production of intracellular IgM and AMA.154,158
Furthermore, the cytotoxicity of liver NK cells in PBC
patients is more profound than cells in control subjects
when incubated with poly I:C and LPS-primed liver macro-
phages.159 These results indicate that patients with PBC
exhibit hypersensitivity to TLR signaling.
Antigen-Presenting Cells
Dendritic Cells
Dendritic cells (DCs) occupy a unique position at the interface
between innate and adaptive immunity, orchestrating a large
panel of responses. The presentation of antigens by immature
DCs should result in immune tolerance, while activated and
mature DCs are capable of priming robust adaptive immune
responses.160 In 1989, Demetris et al ﬁrst identiﬁed dendritic
cells that localize inside the basement membrane between
biliary epithelial cells of septal bile ducts in livers of early stage
PBC.161 Using immunohistochemical methods, Tanimoto et al
reported that there exists activated CD83-positive DCs in PBC
patients.162 In 2001, Akbar et al stimulated peripheral blood T
cells from PBC with either PDC alone or DCs plus PDC. They
reported that peripheral blood T cells from 100% of AMA-
positive PBC patients reﬂected PDC-speciﬁc proliferationwhen
cultured with PDC-pulsed DCs.163 This ﬁnding demonstrated
the effectiveness of antigen-pulsed DCs.
In 2002, Kita et al also found that PDC-E2-speciﬁc cytotoxic
T lymphocytes (CTLs) could also be generated by pulsing DCs
with full-length recombinant PDC-E2 protein, which indicated
that CTL activation could be augmented by immune complexes
cross presented by dendritic cells.164 Hiasa et al analyzed the
phenotypes of DC1 andDC2 frompatientswith primary biliary
cirrhosis.165 A phenotype of DC2 with reduced expression of
HLA D2 and CD123 in PBC may have relevance to the break-
down of tolerance to self-antigen. In addition, Langerhans cells
(LCs) existing around or within biliary epithelial layers are
important as periductal antigen-presenting cells in PBC. The
migration of LCs into bile ducts is closely associated with the
periductal cytokine milieu in patients with PBC.166
Monocytes
Monocytes have also been implicated in the pathogenesis of
PBC and other autoimmune diseases.167 Peripheral-blood
monocytes in PBC are more sensitive to infectious stimuli,
which lead to hypersecretion of proinﬂammatory cytokines.
The expression of TLR4 in circulating monocytes increased
signiﬁcantly after stimulation with lipopolysaccharide (LPS)
in PBC patients, and circulating monocytes produce higher
proinﬂammatory cytokines, including IL-1β, IL-6, IL-8, and
TNF-α169, that can amplify adaptive T-cell–mediated immune
responses against pathogens. At the same time, the level of
RP105, which is involved in the negative regulation of TLR4
signaling, is decreased in PBCmonocytes.168 In the liver of PBC
patients, TLR3 is highly expressed onmacrophages surround-
ing the portal tract and on hepatocytes, and these macro-
phages produce type-I interferon through TLR-3 signaling.169
The complexity of the immune response is illustrated by the
fact that the proinﬂammatory cytokine IL-6 has been found to
play a role in activation of IL-10 producing Tr1 cells in
suppressing autoimmune tissue inﬂammation.170,171
Biliary Epithelial Cells
Biliary epithelial cells (BECs) are not just innocent bystanders
in the pathophysiology of PBC.172 First, unlike other epithelial
cells, BECs act as antigen-presenting cells that express HLA
class II173,174 and costimulatory molecules, such as CD80 and
CD86.175,176 After phagocytosing and processing the apopto-
tic BECs, BECs present novel mitochondrial self-peptides in
conjunction with HLA class II.80,176,177 Finally, autoreactive T
cells against 2-OADC inﬁltrate into the liver,178 and gather
around small bile ducts. Thiswas observed in PBC irrespective
of their serum AMA status.179 These data support the notion
that phagocytosis of apoptotic cells by nonprofessional phag-
ocytesmay contribute to the tissue speciﬁcity of autoimmune
diseases. Biliary epithelial cells also contribute to the defense
mechanisms against infectious agents by recognition of
PAMPs via speciﬁc membrane TLRs, resulting in the genera-
tion of chemokines that activate both the innate and adaptive
immunity systems. Biliary epithelial cells are unique in
secreting immunoglobulins A of the secretory type (sIgA)
through transcytosis in the biliary lumen, which may consti-
tute organ-speciﬁc immune-mediated injury.180,181
Natural Killer Cells
Natural killer cells are mainly involved in defense against
infections and tumors, but also link innate with adaptive
immunity. Several studies indicate that aberrancies in NK-
cell-mediated immune homeostasis can lead to the onset of
autoimmune diseases.182 In 2001, Panasiuket alﬁrst reported
the increase of NK cell numbers in the peripheral blood of PBC
patients.183 The ﬁnding has been conﬁrmed by Chuang and
his colleagues, and it was further demonstrated that NK cells
express higher levels of perforin and decreased cytokine
production in PBC patients compared with healthy con-
trols.184 At the same time, a higher frequency of CD56dim/
CD16pos hepatic NK cells was present within the liver of PBC
patients. Further studies have shown that hepatic NK cells
have cytotoxic activity against autologous biliary epithelial
cells.
Because NK cells have been reported to express CX3CR1
and CXCR3, it has been hypothesized that the higher
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frequency of cytotoxic NK cells found in the liver of PBC is due
to an increased migration of circulating NK cells through
mechanisms that involve both CX3CR1 and CXCR3. In amouse
model, there is a marked suppression of AMA and cytokine
production from autoreactive T cells after in vivo depletion of
NK and natural killer T (NKT) cells.185 The increased inﬁltra-
tion of cytotoxic NK cells in the liver may reﬂect the break-
down of NK cell immune tolerance, but further studies are
needed to describe the detailed mechanisms driving the
expansion of autoreactive NK cells.186
Natural Killer T Cells
Natural killer T cells are regulated by self- and nonself-
glycolipid antigens that are presented by the antigen-pre-
sentingmolecule CD1d. This process allows for rapid NKT cell
expression of effector cytokines and chemokines, thereby
modulating both innate and adaptive immune responses. In
PBC, the frequency and absolute number of blood and liver
NKT cells are markedly increased compared with healthy
controls. Moreover, cytotoxic activity and perforin expression
by isolated NKT cells were signiﬁcantly increased in PBC with
increased IL-8 levels and expression of CD128a (IL-8 receptor)
on NKT cells. In contrast, the levels of interferon-γ (IFN-γ), IL-
6, and IL-8 synthesized by NKT cells were signiﬁcantly
decreased in PBC when compared with controls.187 In
2008, Chuang et al generated a CD1d(/  ) dnTGF-nRII
mice and reported decreased hepatic lymphoid cell inﬁltra-
tion aswell asmilder cholangitis than that seen in controls.188
CD1d-restricted NKT cells in the liver exhibit increased IFN-γ
production after exposure toα-galactosylceramide. In bothN.
aromaticivorans induced and 2-OA-BSA induced PBC mouse
models, NKT cells are involved in disease exacerbations,
which include signs of portal inﬂammation, bile duct destruc-
tion, and liver ﬁbrosis.58,189
Adaptive Immunity: Cellular Immunity
Excessive T-Cell Helper Function
An enhanced ratio of Th1 toTh2 cells is an important factor in
the onset of PBC.190,191 Th17cells, a subset of CD4 T cells,
accumulate around damaged bile ducts in liver and in a
mouse model of PBC.192 In IL-2Rα(–/ – ) mice, marked aggre-
gation of IL-17þ cells within portal tracts compared with the
periphery has been demonstrated. Interestingly, CD4þ T cells
from the livers of normal C57BL/6J mice can secrete higher
levels of IL-17 comparedwith those from spleens, indicating a
role of the liver microenvironment in Th17 induction. Finally,
Th17 cells involved in the pathogenesis of various autoim-
mune diseases are also constituents of the periductular
inﬁltrates in human PBC.193,194 In recent studies, our prelim-
inary data demonstrated that the frequency of T follicular
helper cells are more highly expressed in PBC patients, and
that Tfh accumulates around the damaged bile ducts in liver
tissue.
T-Cell Regulation
CD4 þ CD25þ T regulatory cells (Tregs) play an important
role in themaintenance of peripheral self-tolerance as well as
downregulation of various immune responses.24,25 In PBC
patients, FoxP3þ Tregs can be identiﬁed in the lymphoid
inﬁltrates localized to portal tracts, and signiﬁcantly lower
proportions of circulating CD4 þ CD25highTregs are observed
in patients and family members.195 In addition, the
dnTGFβRII and IL-2Rα knockout murine models support a
role of Tregs deﬁciency in loss of immune tolerance. The
selective deﬁciency of the TGFβ R-signaling pathway exclu-
sively in T lymphocytes accounts for major impairments of
peripheral tolerance as Treg cells depend on TGFβ for their
regulatory activity. The result is the triggering of tissue-
speciﬁc autoreactive effector T cells.39 A mouse deﬁcient
for IL-2 receptor α (IL-2Rα), which is highly expressed on
Tregs, developed 100% AMA positivity against PDC-E2, 80%
antinuclear antibody (ANA) positivity, and lymphocyte inﬁl-
tration around the portal tracts associatedwith cholangiocyte
injury.38
In 2009, Zhang et al studied Scurfy (Sf) mice, which have a
mutation in the gene encoding the Foxp3 transcription factor
resulting in a complete abolition of Foxp3þ Tregs. At 3 to
4 weeks of age, 100% of animals manifested high titers of
serum AMA of all isotypes. Furthermore, these mice had
moderate to severe lymphocytic inﬁltrates surrounding por-
tal areas with evidence of biliary duct damage. These data
illustrate that lacking normal Treg function is a major pre-
disposing feature for breach of tolerance that leads to
PBC.196,197
Other regulatory cells, such as CD8 Tregs have also been
reported to contribute to a signiﬁcant phenotypic alteration
in PBC patients characterized by increased expression of
CD127 and reduced CD39 compared with normal controls.
Furthermore, in vitro induction of CD8 Tregs by incubation
with IL-10 is signiﬁcantly reduced in PBC.198 The immuno-
modulatory effects of the tryptophan-catabolizing enzyme
indoleamine-2,3-dioxygenase (IDO) have been studied at a
cellular level and implicated in the pathogenesis of several
complex diseases. Impaired IDO production has been re-
ported and postulated to contribute to the development of
disease pathogenesis in PBC patients.199
Expansion of the Autoreactive T-Cell Pool
Under normal circumstances, lymphocytes are scattered
throughout the liver parenchyma, as well as in the portal
tracts. These lymphocytes belong to several subpopula-
tions.200 T-helper (CD4 þ ) TCR αβþ and CD8þ T cells are
present in portal tracts and around damaged bile ducts,
strongly supporting their role in the development of biliary
damage.201–207 Autoreactive CD4 T cells that speciﬁcally
target PDC-E2-self-antigen are present in peripheral blood
and liver. There is a 100- to150-fold increase in the number of
PDC-E2-speciﬁc CD4 T cells in the hilar lymph nodes and liver
versus peripheral blood in patientswith PBC.203 TheHLA class
I restricted epitope for CD8 T cells, namely the 159–167 aa
sequence,maps in close vicinity to the epitopes recognized by
CD4 T cells as well as by AMA.59 Notably, the autoepitope for
both CD4 and CD8 T cells overlaps with its B-cell (AMA)
epitope, including the inner lipoyl domain. Similar to CD4
autoreactive T cells, there is a 10-fold higher frequency of
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PDC-E2 159–167 speciﬁc CD8 T cells in liver compared with
blood. Moreover, the frequency of precursor of PDC-E2-spe-
ciﬁc autoreactive CD8 T cells is signiﬁcantly higher in early-
rather than late-stage disease.208 The autoreactive CD8 T cells
in PBC produce IFN-γ rather than IL-4/IL-10 cytokines. Autor-
eactive CD8 T cells have also been implicated in hepatocyte
damage seen in autoimmune hepatitis.209
Adaptive Immunity: Humoral Immunity
A high titer of serum AMA can be detected in up to 95% of
patients with PBC. Antimitochondrial antibodies can be de-
tected even before clinical symptoms or biochemical anoma-
lies. However, most studies have shown that there is no
correlation between the level of serum AMA and the severity
of PBC. Antimitochondrial antibody positivity alone also does
not predict the patient’s response to treatment with urso-
deoxycholic acid (UDCA). However, AMA-IgA can be detected
not only in sera, but also in bile, saliva, and urine of patients
with PBC. In one study, AMA-IgA correlates with disease
severity.210 In addition to AMAs, ANAs are detected in nearly
50% of patients with PBC, and their presencemay be clinically
signiﬁcant.211,212
Although B cells are well known for their antibody pro-
duction, they also participate in antigen presentation, model-
ing of the spleen architecture, and Th1/Th2 polarization of T
cells.213 Speciﬁc substrates of B cells can act as negative
regulators and facilitate immune tolerance. In the liver of
PBC patients, the number of inﬁltrating B cells is higher than
that of PSC patients and normal controls. Moreover, the
proportion of CD19 þ CD69þ activated B cells is markedly
higher in liver than in peripheral blood in PBC, and the
number of AMA-producing cells is ﬁve-fold greater in liver
than in PBMCs.214 In 2012, Takahashi et al reported a unique
coronal arrangement of CD38þ cells around the intrahepatic
bile ducts in PBC, but not in controls; therewas an association
with AMA titer and an inverse association with serum γ-
glutamyltranspeptidase levels.215
In a dnTGF-βRII PBC mouse model, anti-CD20 adminis-
tered every 2 weeks ameliorated autoimmune cholangitis if
given early in the disease process.216 In PBC, a regimen of two
doses of 1000 mg rituximab (mouse-human chimeric anti-
CD20 monoclonal antibody) separated by 2 weeks was found
to be safe, but onlymarginally effective in some patients, who
had an incomplete UDCA response.217 In 2-octynoic acid-
Table 3 Novel approaches that may restore immune tolerance in primary biliary cirrhosis
Treatment target Possible mechanisms Treatment efficacy
Traditional
UDCA (13–15 mg/kg/d) Bile acid pool Not clear (involving choleresis,
antiapoptosis, anti-
inﬂammation)
About 60% efﬁcacy
Nonspeciﬁc immunosuppression
Budesonide219,255
Methotrexate and colchicine220
Cyclosporine221
Azathioprine222
Whole activated
immune systems
(autoimmune or
nonspeciﬁc
immune)
Immunosuppression Transitory biochemical
response in some patients,
but with side effects
Speciﬁc target therapy
Rituximab216,217 Total B cells Depletion B cells Limited efﬁcacy in patients
Ustekinumab226 IL-12/IL-23 Block the signal pathway of IL-
12
In progress (NCT01389973)
NI-0801 CXCR10 (IP-10) Inhibits T-cell migration and
inﬂammation
In progress (NCT01430429)
CTLA4/immunoglobulin
230
CTLA4 Inhibits T-cell activation In preclinical studies
Novel therapeutic methods
Mesenchymal stem cells234,235 Whole activated
immune systems
and damaged bile
ducts
Potential immunomodulatory
capacity; tissue regeneration
and repair
Pilot data in PBC patients;
signiﬁcant beneﬁts in
mouse models
Tolerogenic dendritic
cell (tolDCs) vaccine
DC Induce immune tolerance to
PDC
In theoretical stages
Oral tolerance238 Immune system Induce immune tolerance to
PDC
failed
SiRNA or microRNA Key molecular Restore immune tolerance In theoretical stages
Abbreviations: DC, dendritic cell; IL, interleukin; PBC, primary biliary cirrhosis; PDC, pyruvate dehydrogenase complex; UDCA, ursodeoxycholic acid.
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bovine serum albumin (2OA-BSA)-induced mice, treatment
with anti-CD20 and anti-CD79 antibodies led to a higher
number CD4þ and CD8þ T cells around damaged bile ducts in
portal areas, which manifest as more severe cholangitis.218
Adoptive transfer of CD19þ cells from dnTGF-βRII mice into
recombination activating gene-1 (Rag-1)(/  ) mice re-
sulted in decreased liver inﬂammation and bile duct dam-
age.216 Together, these ﬁndings suggest that there is a
subclass of B cells that has a regulatory role by producing
IL-10. However, further studies are needed to explore the
functions of B cells in PBC.
Novel Approaches to Restore Immune
Tolerance in Primary Biliary Cirrhosis
Currently, UDCA is the only drug approved by the Food and
Drug Administration to treat PBC patients. Early treatment
with UDCA at a dose of 13 to 15 mg/kg per day can delay the
progression of histological changes, ameliorate long-term
morbidity, and prolong life expectancy. Ursodeoxycholic
acid acts by increasing the hydrophilic properties of the
bile acid pool, producing bicarbonate-rich choleresis, which
protects against hepatocellular damage. However, over 40% of
patients have an incomplete response to UDCA, resulting in
progressive disease necessitating liver transplantation or
ultimately resulting in death from liver-related causes. There-
fore, future studies should focus on the development of novel
approaches that restore the immune tolerance in PBC
(►Table 3).
Unlike other autoimmune diseases, nonspeciﬁc immuno-
suppressive medication is not recommended as a ﬁrst-line
strategy for PBC. But it is sometimes used in patients who fail
to respond toUDCA. In 2000, Angulo et al treated PBC patients
who had an incomplete response to UDCA therapy with
budesonide, a corticosteroid with an extensive ﬁrst-pass
hepatic metabolism.219 After 1-year treatment, there was a
signiﬁcant but transitory improvement in serum levels of
total bilirubin, and a signiﬁcant but marginal improvement in
serum alkaline phosphatase. The Mayo risk score increased
signiﬁcantly, and there was a signiﬁcant loss of bone mass of
the lumbar spine. In 2010, Kaplan et al treated PBC patients
who had not responded fully to UDCAwithmethotrexate and
colchicine.220 The result showed that methotrexate and
colchicine signiﬁcantly improved liver enzyme tests and liver
histology. Others, like cyclosporine,221 azathioprine222 were
also used to treat PBC patients. However, these nonspeciﬁc
immunosuppression drugs not only suppressed the underly-
ing autoimmune disease, but also led to global suppression of
the immune system. The results of this approach include side
effects such as increased risk of infection, carcinogenesis, and
osteoporosis. There is a clear need for more speciﬁc strategies
to restore immune tolerance to the speciﬁc autoantigens
implicated in disease pathology.
Ideally, autoimmune disease therapies would uniquely
target the speciﬁc autoreactive lymphocyte populations,
while leaving unperturbed the rest of the immune system.
Primate or humanized monoclonal antibodies against pan-T
cell or B cells as well as leukocyte-speciﬁc antigens or soluble
receptors have been used extensively in the treatment of
autoimmune diseases.223 Several antibodies targeting specif-
ic cells or signaling pathways have been also applied in PBC
patients.
In PBC patients, although the role of B cells in the
pathogenesis is not clearly deﬁned, B-cell depletion thera-
py has been shown to be of potential value. The concept of B
cell depletion was ﬁrst tried in a PBC mice model, Moritoki
et al showed that in younger dominant-negative TGF-βRII
mice aged 4 to 6 weeks, anti-CD20 treatment signiﬁcantly
alleviated liver inﬂammation and reduced bile duct dam-
age.216 Rituximab is a mouse-human chimeric anti-CD20
monoclonal antibody designed for B-cell depletion therapy
in humans. It has been approved for the treatment of
lymphoma and certain autoimmune diseases such as rheu-
matoid arthritis. Tsuda et al used rituximab to treat six
patients with PBC who had suboptimal biochemical re-
sponse to UDCA.217 After B-cell depletion, they observed a
reduction in the number of AMA-producing B cells, AMA
titers, serum alkaline phosphatase levels (ALP), and plasma
levels of immunoglobulins (IgA, IgM, and IgG) at week 24.
As the levels of immunoglobulins, AMA titers and ALP
returned to baseline levels at week 36, repeated anti-
CD20 treatment was suggested to maintain the treatment
effect. However, there were two patients who experienced
upper respiratory infection and reactivation of varicella
zoster after the ﬁrst infusion. Further clinical studies
targeting B cells in PBC patients are warranted.224
Interleukin-12 (IL-12) and its receptors have been identi-
ﬁed as susceptibility genes for PBC, and play a very important
role in the breakdown of immune tolerance, thereby offering
another potential therapeutic target.225 Ustekinumab,226 a
humanmonoclonal antibody directed against IL-12 and IL-23,
is involved in immune regulation and has the potential to
mediate certain autoimmune diseases such as active psoriasis
arthritis.227 A phase II clinical trial (NCT01389973) using
ustekinumab to treat PBC patients is in progress.
CXCL-10 has been shown to play a role in autoimmuni-
ty.228 Plasma and portal IFN-γ-inducible protein-10 (IP-10)
levels were found to be increased in PBC patients compared
with controls.229 NI-0801, an anti-CXCL10 monoclonal anti-
body that inhibits T-cell migration and inﬂammation, is being
studied in the treatment of PBC patients in a phase II clinical
trial (NCT01430429). Other speciﬁc antibody treatments,
such as those targeting CTLA4/immunoglobulin,230,231 are
also in preclinical studies in mouse models, and offer other
potential areas of pharmaceutical development in the treat-
ment of PBC.232
Mesenchymal Stem Cells: Re-establishing Immune
Tolerance
Mesenchymal stem cells (MSCs) have been used as a thera-
peutic strategy for tissue regeneration and repair, and their
potential immunomodulatory capacity, especially in the in-
duction of immune tolerance, has raised signiﬁcant clinical
interest. Recently, autologous and allogeneic MSCs have been
reported to signiﬁcantly improve symptoms in patients with
severe autoimmune diseases, such as Crohn disease, multiple
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sclerosis, refractory systemic lupus erythematosus, and sys-
temic sclerosis.233
Mesenchymal stem cells have also been used in mouse
models of PBC. In 2011,Wang et al used bonemarrow-derived
mesenchymal stem cells (BM-MSC) in treatment of polyino-
sinic-cytidylic acid poly (I:C) induced C57BL/6 PBC mouse
model.234 The result showed that after 6 weeks of MSC
infusions, serum aminotransferase and autoimmune anti-
bodies declined, and histological examination showed signif-
icant amelioration of monocyte inﬁltration around bile ducts.
In addition, allogeneic BM-MSC transplantation markedly
increased CD4 þ Foxp3þ regulatory T cells in peripheral
blood as well as lymph nodes. In our pilot studies,235 umbili-
cal cord-derived mesenchymal stem cells (UC-MSCs) were
administered three times at 4-week intervals to seven PBC
patients who were suboptimally treated with UDCA. The
patients were followed for a 48-week period. The result of
this proof of concept study indicated that MSC treatment in
PBC is safe. Fatigue and pruritus were alleviated in most
patients after UC-MSC treatment. There was a signiﬁcant
decrease in serum alkaline phosphatase and γ-glutamyltrans-
ferase levels at the end of the follow-up period as compared
with baseline. A larger, randomized controlled cohort study is
warranted to conﬁrm the clinical efﬁcacy of UC-MSC
transfusion.
Novel Vaccine Therapies
Tolerogenic dendritic cell (tolDCs) vaccines, an antigen-spe-
ciﬁc treatment that only targets the autoreactive inﬂamma-
tory response, has already been proven effective in
experimental animal models of various autoimmune disor-
ders as well as with in vitro experiments using ex vivo
generated human tolDCs.236 A PDC-E2 speciﬁc tolDCs is a
potential strategy for the treatment of PBC.
Induction of oral tolerance by administration of protein
antigens has the potential to induce antigen-speciﬁc immu-
nological unresponsiveness (immune tolerance). High doses
of orally fed antigenmay lead to deletion or anergy of Th cells,
whereas low-dose administration leads to induction of trans-
forming growth factor (TGF)-β-secreting regulatory T cells.237
This approach represents a potential means to prevent or
treat autoimmune disease. Suzuki et al administered 5 mg
PDC in gelatin capsules to six PBC patients for 12 months, but
failed to induce oral tolerance.238
Since the discovery of the RNAi pathway, there has been an
increase in interest in the development of RNAi-based thera-
peutics for “undruggable” targets. Undruggable targets are
those pathogenic molecules that cannot be targeted due to
chemical, structural, or accessibility limitations. Using con-
ventional therapy, only 20% of molecules are targetable.
siRNA therapy has the potential to break this barrier, and has
been used in autoimmune mouse models for rheumatoid
arthritis and Sjögren (SjS) syndrome to restore immune
tolerance.239,240 Similarly, siRNAs or microRNA targeting
special genes might be another potential therapeutic method
for the treatment of PBC patients.241,242
The concept of a breach of immune tolerance in autoim-
mune diseasemay change thewaywe think about PBC and its
treatment. In the future, novel therapeutic approaches based
on restoration of immune tolerance will be developed to
maintain disease remission with minimal ongoing treatment
or a drug-free regimen (such as stem cell therapy) rather than
the use of general immunosuppressive agents.243
Summary
In PBC, considerable progress has been made in understand-
ing the basic mechanisms of the breach of tolerance, but our
knowledge is still incomplete.
In most autoimmune diseases, the treatment generally
involves immunosuppression. In PBC, most immunosuppres-
sive agents have proven to be relatively ineffective.244 This
indicates that the pathogenesis of PBC is not simply an over-
reactive immune system directed against a self-antigen, but
more likely involves an imbalance in immune tolerance that is
affected by many different factors. The speciﬁc role of these
factors, which may include those that are involved in innate
immunity, and additionally those that are involved in cellular
regulation, such as T regulatory cells, is not completed
elucidated.
Primary biliary cirrhosis, being a chronic liver disease, is
generally characterized by a slow progression but a highly
variable clinical course. The clinical features and natural
history of the disease vary greatly between patients, ranging
from asymptomatic and slowly progressive to symptomatic
and rapidly evolving to decompensated status. However, very
little is known about the relationship between the variable
clinical course of PBC and its immune tolerance state. More-
over, the exact time point of the breach in immune tolerance
is unclear. Whether it occurs in asymptomatic clinical stages
when AMAmay be detected, or only in liver biopsy stage I and
beyond where the disease has progressed to small bile duct
damage needs to be further elaborated.
It is unclear where the breach in tolerance in PBC origi-
nates. Tolerance is regulated by both innate and adaptive
immunity, and PBCmay occur through different mechanisms.
This is illustrated by the fact that some PBC patients are AMA
positive, while others are AMA negative, but patients lacking
AMAs present with similar disease characteristics and pro-
gression as AMA-positive patients. The quality of life and life
expectancy in responders to UDCA treatment are comparable
with the general population. However, the 40% of patients
who are UDCA unresponders exhibit a muchmore aggressive
disease progression that can lead to liver transplantation. The
mechanisms that affect UDCA responsiveness may be a
combination of genetic factors and environmental exposures.
There are other factors that may also play a role in the
breach of immune tolerance in PBC patients. The majority of
the patients are in their sixth decade of life at the time of
diagnosis of PBC. Immunosenescence (aging of the immune
system), which may result in a decline of T- and B-cell
function, may be accompanied by a loss of ability to differen-
tiate “self” and “foreign” antigens and may contribute to the
development of PBC. Finally, further research is needed to
decipher the extent of the involvement of various compo-
nents in the pathogenesis of PBC. Novel approaches that are
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based on an understanding of the detailed mechanisms may
then be developed and used to improve treatment efﬁcacy in
the future.
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